Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma

NCT02204982 is registered in ClinicalTrials.gov with SecuraBio as lead sponsor.

NCT NCT02204982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02204982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Lead sponsor
SecuraBio
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2014
Completion date
March 31, 2017
Enrollment
13 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma